Skip to main content

Table 2 Circulating biomarkers and neutrophils stimulation profiles for patients with and without coronary allograph vasculopathy (CAV)

From: Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients

Parameters

CAV ( n  = 7)

No CAV ( n  = 11)

Biomarkers

  

VEGF-A165

63.3 ± 27.8

48.4 ± 15.1

IL-8

6.20 ± 1.59

3.61 ± 0.74

IL-RA

331 ± 99

187 ± 30

Neutrophils/Factors

  

VEGF release

  

 PBS

10.5 ± 2.8

11.7 ± 1.9

 fMLP

47.1 ± 9.5

52.7 ± 9.3

 LPS

33.4 ± 5.5

46.7 ± 8.9

 TNF-α

51.7 ± 11.4

60.7 ± 10.6

IL-8 release

  

 PBS

23.7 ± 5.3

14.7 ± 2.8

 fMLP

115 ± 19

161 ± 20

 LPS

1100 ± 115

1180 ± 67

 TNF-α

728 ± 81

898 ± 76

IL-1RA release

  

 PBS

187 ± 43

229 ± 44

 fMLP

178 ± 43

248 ± 42

 LPS

253 ± 52

357 ± 54

 TNF-α

457 ± 66

515 ± 55

  1. CAV: Cardiac allograft vasculopathy; VEGF: Vascular endothelial growth factor; IL: Interleukin; RA: Receptor antagonist; PBS: Vehicule; fMLP: N-formyl-Met-Leu-Phe; LPS: Bacterial lipopolysaccharides; TNF: Tumor necrosis factor. Variables are expressed as mean ± SEM and percentages.
Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us